{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T15:35:31Z","timestamp":1777044931394,"version":"3.51.4"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,7,14]],"date-time":"2020-07-14T00:00:00Z","timestamp":1594684800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.biopha.2020.110536","type":"journal-article","created":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T17:50:55Z","timestamp":1595008255000},"page":"110536","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["PARP-inhibitors in a non\u2010oncological indication as COVID-19: Are we aware about its potential role as anti-thrombotic drugs? The discussion is open"],"prefix":"10.1016","volume":"130","author":[{"given":"Ettore","family":"Capoluongo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.biopha.2020.110536_bib0005","doi-asserted-by":"crossref","DOI":"10.3390\/v12040372","article-title":"Virology, epidemiology, pathogenesis, and control of COVID-19","volume":"12","author":"Jin","year":"2020","journal-title":"Viruses."},{"key":"10.1016\/j.biopha.2020.110536_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2020.102433","article-title":"The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak","volume":"109","author":"Rothan","year":"2020","journal-title":"J. Autoimmun"},{"issue":"April 24","key":"10.1016\/j.biopha.2020.110536_bib0015","article-title":"The friendly use of chloroquine in the COVID-19 disease: a warning for the G6PD-deficient males and for the unaware carriers of pathogenic alterations of the G6PD gene","author":"Capoluongo","year":"2020","journal-title":"Clin. Chem. Lab. Med."},{"issue":"8","key":"10.1016\/j.biopha.2020.110536_bib0020","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph17082690","article-title":"Coronavirus diseases (COVID-19) current status and future perspectives: a narrative review","volume":"17","author":"Di Gennaro","year":"2020","journal-title":"Int. J. Environ. Res. Public Health"},{"issue":"May 5","key":"10.1016\/j.biopha.2020.110536_bib0025","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1111\/jth.14817","article-title":"Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy","volume":"18","author":"Tang","year":"2020","journal-title":"J. Thromb. Haemost."},{"issue":"5","key":"10.1016\/j.biopha.2020.110536_bib0030","first-page":"001646","article-title":"Deep Vein Thrombosis and Pulmonary Embolism: Two Complications of COVID-19 Pneumonia?","volume":"7","author":"Poggiali","year":"2020","journal-title":"Eur. J. Case. Rep Intern. Med."},{"key":"10.1016\/j.biopha.2020.110536_bib0035","first-page":"12","article-title":"More on COVID-19 coagulopathy in caucasian patients","author":"Fogarty","year":"2020","journal-title":"Br. J. Haematol."},{"issue":"10231","key":"10.1016\/j.biopha.2020.110536_bib0040","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/S0140-6736(20)30627-9","article-title":"COVID-19 and Italy: what next?","volume":"395","author":"Remuzzi","year":"2020","journal-title":"Lancet"},{"issue":"May 11","key":"10.1016\/j.biopha.2020.110536_bib0045","article-title":"More on: \u201cCOVID-19 coagulopathy in caucasian patients\u201d","author":"Marietta","year":"2020","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.biopha.2020.110536_bib0050","doi-asserted-by":"crossref","DOI":"10.1111\/jth.14810","article-title":"ISTH interim guidance on recognition and management of coagulopathy in COVID-19","author":"Thachil","year":"2020","journal-title":"J Thromb Hemost."},{"issue":"3","key":"10.1016\/j.biopha.2020.110536_bib0055","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1142\/S0192415X20500378","article-title":"COVID-19: an update on the epidemiological, clinical, preventive and therapeutic evidence and guidelines of integrative Chinese-western medicine for the management of 2019 novel coronavirus disease","volume":"48","author":"Chan","year":"2020","journal-title":"Am. J. Chin. Med."},{"key":"10.1016\/j.biopha.2020.110536_bib0060","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/bph.13748","article-title":"Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases","volume":"175","author":"Berger","year":"2018","journal-title":"Br. J. Pharmacol."},{"issue":"7","key":"10.1016\/j.biopha.2020.110536_bib0065","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21072657","article-title":"A review of SARS-CoV-2 and the ongoing clinical trials","volume":"21","author":"Tu","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2020.110536_bib0070","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1038\/ejhg.2016.92","article-title":"BRCA to the future: towards best testing practice in the era of personalised healthcare","volume":"1","author":"Capoluongo","year":"2016","journal-title":"Eur. J. Hum. Genet."},{"issue":"1","key":"10.1016\/j.biopha.2020.110536_bib0075","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1080\/02656736.2018.1503346","article-title":"Upfront HIPEC and bevacizumab-containing adjuvant chemotherapy in advanced epithelial ovarian cancer","volume":"35","author":"Paris","year":"2018","journal-title":"Int. J. Hyperthermia"},{"issue":"November 12","key":"10.1016\/j.biopha.2020.110536_bib0080","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1245\/s10434-018-6700-6","article-title":"BRCA mutation status to personalize management of recurrent ovarian Cancer: a multicenter study","volume":"25","author":"Marchetti","year":"2018","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.biopha.2020.110536_bib0085","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1093\/annonc\/mdv608","article-title":"Prospective phase II trial of trabectedin in BRCA-mutated and\/or BRCAness phenotype recurrent ovarian cancer patients: the MITO 15 trial","volume":"27","author":"Lorusso","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.biopha.2020.110536_bib0090","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s11523-019-00680-2","article-title":"PARP inhibition in Cancer: an update on clinical development","volume":"14","author":"Sachdev","year":"2019","journal-title":"Target. Oncol."},{"key":"10.1016\/j.biopha.2020.110536_bib0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110204","article-title":"Therapeutic applications of PARP inhibitors in ovarian Cancer","volume":"127","author":"Xie","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.biopha.2020.110536_bib0100","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s11523-017-0496-3","article-title":"Retrospective evaluation of thromboembolism risk in ovarian Cancer patients treated with bevacizumab","volume":"12","author":"Kuk","year":"2017","journal-title":"Target. Oncol."},{"key":"10.1016\/j.biopha.2020.110536_bib0105","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1161\/ATVBAHA.107.156406","article-title":"PARP-1 inhibition prevents oxidative and nitrosative stress-induced endothelial cell death via transactivation of the VEGF receptor 2","volume":"28","author":"Mathews","year":"2008","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.biopha.2020.110536_bib0110","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.2217\/fon-2018-0751","article-title":"Advances in the use of PARP inhibitors for BRCA1\/2-associated breast cancer: talazoparib","volume":"15","author":"McCann","year":"2019","journal-title":"Future Oncol."},{"issue":"May 22","key":"10.1016\/j.biopha.2020.110536_bib0115","article-title":"Repositioning PARP inhibitors for SARS\u2010CoV\u20102 infection (COVID\u201019); a new multi\u2010pronged therapy for ARDS?","author":"Curtin","year":"2020","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.biopha.2020.110536_bib0120","article-title":"A data-driven drug repositioning framework discovered a potential therapeutic agent targeting COVID-19","author":"Ge","year":"2020","journal-title":"bioRxiv preprint"}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332220307290?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332220307290?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T18:09:27Z","timestamp":1766081367000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332220307290"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":24,"alternative-id":["S0753332220307290"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2020.110536","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PARP-inhibitors in a non\u2010oncological indication as COVID-19: Are we aware about its potential role as anti-thrombotic drugs? The discussion is open","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2020.110536","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"110536"}}